Asymchem(002821)2025-04-24 13:28Financial Performance - Q1 2025 revenue reached 1.541 billion RMB, representing a 10.1% increase compared to Q1 2024 [7] - Gross profit for Q1 2025 was 655 million RMB, with a gross margin of 42.5% [29] - Net profit attributable to shareholders was 327 million RMB, reflecting a 15.8% increase year-on-year [29] Cost Management - The company implemented cost reduction and efficiency improvement measures, resulting in a net profit growth rate that exceeded revenue growth by 5.7 percentage points [8] - Selling expenses as a percentage of revenue were 2.9% in Q1 2025, down from 3.2% in Q1 2024 [11] - Management expenses accounted for 11.9% of revenue in Q1 2025, a decrease from 12.3% in Q1 2024 [12] Business Segments - Small molecule CDMO business revenue remained stable with a gross margin of 45.2% [7] - Emerging business revenue grew over 80% with a gross margin of 33.1% [7] Future Outlook - The company anticipates double-digit revenue growth for the full year 2025, supported by ongoing cost management and market expansion efforts [26] - Focus on enhancing competitiveness in peptide, oligonucleotide, and ADC businesses to ensure sustained growth [26] - Plans to deepen overseas commercialization capacity while balancing strategic implementation and operational cost control [26]